Erasca (ERAS) Competitors

Beam Therapeutics (NASDAQ:BEAM) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, community ranking, profitability, media sentiment, valuation and analyst recommendations.

Does the MarketBeat Community believe in BEAM or ERAS?

Beam Therapeutics received 38 more outperform votes than Erasca when rated by MarketBeat users. However, 73.17% of users gave Erasca an outperform vote while only 59.13% of users gave Beam Therapeutics an outperform vote.

Company	Underperform	Outperform
Beam Therapeutics	Outperform Votes 68 59.13%	Underperform Votes 47 40.87%
Erasca	Outperform Votes 30 73.17%	Underperform Votes 11 26.83%

Does the media refer more to BEAM or ERAS?

In the previous week, Beam Therapeutics had 7 more articles in the media than Erasca. MarketBeat recorded 8 mentions for Beam Therapeutics and 1 mentions for Erasca. Erasca's average media sentiment score of 1.02 beat Beam Therapeutics' score of 0.67 indicating that Erasca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Erasca	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate BEAM or ERAS?

Beam Therapeutics currently has a consensus price target of $48.75, indicating a potential upside of 192.62%. Erasca has a consensus price target of $4.57, indicating a potential upside of 237.37%. Given Erasca's higher possible upside, analysts clearly believe Erasca is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Erasca	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders believe in BEAM or ERAS?

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 3.5% of Beam Therapeutics shares are held by company insiders. Comparatively, 14.4% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more risk and volatility, BEAM or ERAS?

Beam Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Is BEAM or ERAS more profitable?

Erasca has a net margin of 0.00% compared to Beam Therapeutics' net margin of -609.24%. Erasca's return on equity of -36.56% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-609.24%	-44.24%	-30.97%
Erasca	N/A	-36.56%	-31.08%

Which has preferable valuation and earnings, BEAM or ERAS?

Erasca has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$63.52M	26.37	-$376.74M	-$4.61	-3.61
Erasca	N/A	N/A	-$161.65M	-$0.62	-2.19

Summary

Erasca beats Beam Therapeutics on 9 of the 17 factors compared between the two stocks.